Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bafna Pharmaceuticals Limited ( (IN:BAFNAPH) ) has shared an update.
Bafna Pharmaceuticals Limited has submitted to the stock exchanges a compliance certificate for the quarter ended 31 December 2025 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the handling of its securities in dematerialised form. Its registrar and share transfer agent, Cameo Corporate Services Limited, certified that all securities received for dematerialisation during the quarter were duly confirmed, listed on the relevant stock exchanges, and that physical certificates were cancelled and replaced in the company’s records with the depositories as registered owners within the prescribed timelines, underscoring the company’s adherence to regulatory requirements in share transfer and depository processes.
More about Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited is an Indian pharmaceutical company based in Chennai, operating in the healthcare and drug manufacturing industry. The company focuses on producing and marketing pharmaceutical formulations, serving domestic and potentially international markets through its manufacturing facilities in Tamil Nadu.
Average Trading Volume: 2,612
Technical Sentiment Signal: Buy
Current Market Cap: 3.48B INR
See more insights into BAFNAPH stock on TipRanks’ Stock Analysis page.